Comprehensive Analysis of CRIP1 in Patients with Ovarian Cancer, including ceRNA Network, Immune-Infiltration Pattern, and Clinical Benefit

Table 2

Logistic regression analysis between CRIP1 expression and clinical characteristics.

Characteristics	Odds ratio (OR)	value
Age (>60 vs. ≤60)	0.954 (0.758-1.200)	0.689
FIGO stage (stage III & stage IV vs. stage I & stage II)	1.909 (1.175-3.176)	0.010
Primary therapy outcome (PD vs. PR & CR)	1.037 (0.663-1.619)	0.872
Histologic grade (G3 & G4 vs. G1 & G2)	1.276 (0.894-1.834)	0.182
Venous invasion (yes vs. no)	1.101 (0.703-1.742)	0.676
Lymphatic invasion (yes vs. no)	1.262 (0.859-1.881)	0.242
Anatomic neoplasm (bilateral vs. unilateral)	1.200 (0.926-1.564)	0.171
Tumor residual (NRD vs. RD)	0.749 (0.544-1.024)	0.072